Compare Liquidia Corporation Common Stock (LQDA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs Twist Bioscience Corp — how do they compare? Liquidia Corporation Common Stock trades at $33.38 (market cap $3.04B), while Twist Bioscience Corp trades at $135.15 (market cap $9.82B). The key difference: Twist Bioscience Corp is far larger — about 3.2× Liquidia Corporation Common Stock's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| LQDA | TWST | |
|---|---|---|
Market Cap | $3.04B | $9.82B |
Volume | 21,111,778 | 2,115,226 |
Sector | Health | Health |
52-Week High | $91.03 | $205.00 |
52-Week Low | $22.02 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.94B | $9.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $151.33, down 0.35% today, near its consensus price target of $153.70. The stock shows a bullish technical signal despite recent earnings misses, with revenue growth improving from $204M in 2022 to $377M in 2025. However, profitability remains a challenge with a net income margin of -31.66% and negative cash flows. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, fueling investor optimism in the healthtech sector.
The outlook balances strong revenue growth and AI partnerships against persistent losses and high valuation multiples. Investment appeal hinges on the company's ability to translate top-line expansion into profitability, with analyst consensus leaning bullish but execution risks remaining elevated for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
